OBJECTIVE: To determine the time it takes for prolactin ( @entity4090 ) levels to increase after initiation of therapy with @entity1767 (a neuroleptic medication) and the pattern and extent of the increase. METHODS: Seventeen individuals scheduled to be given treatment with neuroleptic drugs were enrolled. Baseline blood specimens were collected for @entity4090 and TSH levels. Follow-up samples for @entity4090 determinations were obtained every 3 days for 18 days after initiation of @entity1767 therapy. RESULTS: There were 17 subjects: 14 @entity1 and three @entity1 . Two of the subjects were found to have @entity4089 due to @entity1375 and were excluded from the basic study. The 15 remaining subjects all had normal baseline @entity4090 levels and normal TSH values. The @entity4090 levels in all 15 showed a similar pattern: a rapid increase in @entity4090 levels in the first 6-9 days, followed by a plateau that remained, with minor fluctuations, throughout the study. The highest mean peak level of @entity4090 was 37.4 ng/mL and the maximum was 77 ng/mL. The two individuals with @entity1375 had somewhat elevated baseline @entity4090 levels; although they showed the same initial pattern of increase after @entity1767 administration, their @entity4090 levels reached values well above 100 ng/mL. CONCLUSION: There is a distinct pattern of response of @entity4090 to @entity1767 . The @entity4090 level increases for 6-9 days, then plateaus, the peak being between 30 and 50 ng/mL, and always remains below 77 ng/mL. In our study, levels that continued to increase, or increased above 77 ng/mL, indicated the presence of @entity1375 . The patterns and levels of the increase were uninfluenced by the therapeutic dose of the medication given. Given that the @entity1 in our study with elevated levels of TSH had such high levels of @entity4090 , all @entity1 should have TSH determinations at the initiation of therapy with neuroleptic medications such as @entity1767 .

Pattern of development of @entity4089 after initiation of XXXX therapy.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity4089 :: ('MESH:D006966', 'Disease') :: ['hyperprolactinemia'] @entity1375 :: ('MESH:D007037', 'Disease') :: ['hypothyroidism'] @entity4090 :: ('5617', 'Gene') :: ['PRL'] @entity1767 :: ('MESH:D006220', 'Chemical') :: ['haloperidol']
@entity1767 :: (MESH:D006220,Chemical) :: ['haloperidol']
